Search Results - "Abrams, S. M. L."

Management of hypertensive crisis: British and Irish Hypertension Society Position document by Kulkarni, Spoorthy, Glover, Mark, Kapil, Vikas, Abrams, S. M. L., Partridge, Sarah, McCormack, Terry, Sever, Peter, Delles, Christian, Wilkinson, Ian B.

“…Patients with hypertensive emergencies, malignant hypertension and acute severe hypertension are managed heterogeneously in clinical practice. Initiating…”
Get full text

Aspartame Pharmacokinetics—The Effect of Ageing by PUTHRASINGAM, S., HEYBROEK, W. M., JOHNSTON, A., MASKREY, V., SWIFT, C. G., TURNER, P., ABRAMS, S. M. L., JACKSON, S. H. D.

“…Aspartame is an intense sweetener which is increasingly used in the UK. It is registered at an acceptable daily intake (ADI) of 40mg/kg, although there are no…”
Get full text

Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction by Farthing, M. J., Alstead, E. M., Abrams, S. M., Haug, G., Johnston, A., Hermann, R., Niebch, G., Ruus, P., Molz, K. H., Turner, P.

“…The pharmacokinetics of naftopidil, a novel alpha-1 adrenoceptor-blocking antihypertensive, were investigated in ten patients (9M/1F) with hepatic dysfunction…”
Get full text

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine by LLEDO, P, ABRAMS, S. M. L, JOHNSTON, A, PATEL, M, PEARSON, R. M, TURNER, P

“…Marked interindividual variation has been observed in the pharmacokinetics of the antiarrhythmic agent mexiletine. The fact that its urinary excretion is…”
Get full text

Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite by PIERCE, D. M, ABRAMS, S. M. L, FRANKLIN, R. A

“…Intra- and inter-subject variation in the kinetics of indoramin and its active metabolite 6-hydroxyindoramin have been studied in 5 young, healthy, male…”
Get full text

Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects by PIERCE, D. M, ABRAMS, S. M. L, FRANKLIN, R. A

“…We have studied the pharmacokinetics and absolute systemic availability of indoramin (50 mg) given orally in solution or as a tablet with reference to…”
Get full text

1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial by Baker, Laurence R.I., Abrams, S. M. Louise, Roe, Christopher J., Faugere, Marie-Claude, Fanti, Paolo, Subayti, Yahya, Malluche, Hartmut H.

“…1,25(OH)2D3 administration in moderate renal failure: A prospective double blind trial. This study represents the first randomized prospective, double-blind,…”
Get full text

Healthy volunteers and alcohol abuse by Abrams, S M, Shah, G

Get more information

Early therapy of renal bone disease with calcitriol: a prospective double-blind study by Baker, L R, Abrams, S M, Roe, C J, Faugere, M C, Fanti, P, Subayti, Y, Malluche, H H

“…The value of calcitriol administration in the management and prevention of renal bone disease was studied in a prospective double-blind manner in 16 patients…”
Get more information

Platelet hyperreactivity and inefficient spontaneous thrombolysis in patients at high risk from an acute coronary event by Peters, N S, Abrams, L S, Dymond, D S, Kovacs, I B

“…We conducted a retrospective study to correlate thrombotic variables with the risk from an acute coronary event, using a new in vitro technique, which measures…”
Get more information

Neurotransmitters and drugs by Abrams, S. M. L.

Get full text

Circadian variation in theophylline absorption during chronic dosing with a slow release theophylline preparation and the effect of clock time of dosing by Jackson, SH, Johnston, A, Woollard, R, Abrams, SM, Turner, P

“…1. Eight volunteers were given seven doses of 200 mg of slow release theophylline at either 11.00 h and 23.00 h (regimen 1) or 17.00 h and 05.00 h (regimen 2)…”
Get full text

Indomethacin and protein binding of methotrexate by Raveendran, R, Heybroek, W, Caulfield, M, Lawson, M, Abrams, S M, Wrigley, P F, Slevin, M, Turner, P

“…Indomethacin, a non-steroidal anti-inflammatory drug is known to increase the efficacy and toxicity of methotrexate, the widely used anti-cancer drug in man…”
Get more information

Controlled trial of calcitriol in hemodialysis patients by Baker, L R, Muir, J W, Sharman, V L, Abrams, S M, Greenwood, R N, Cattell, W R, Goodwin, F J, Marsh, F P, Adami, S, Hately, W

“…We report on a 5-year, prospective, double-blind trial of 1,25 dihydroxycholecalciferol (calcitriol) versus placebo in 76 hemodialysis patients without…”
Get more information

Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment by Abrams, S. M., Baker, L. R., Crome, P., White, A. S., Johnston, A., Ankier, S. I., Warrington, S. J., Turner, P., Niebch, G.

“…The pharmacokinetics of flupirtine after a single oral dose of 100mg have been studied in patients with moderate renal impairment and in healthy elderly…”
Get full text

The role of alpha-adrenoceptor blockade in the treatment of hypertension by Abrams, S M, Turner, P

“…Early attempts to use alpha-adrenoceptor blockers in the treatment of hypertension were unsuccessful due to a high prevalence of side-effects. Now that the…”
Get more information

Pharmacokinetic interaction between indoramin and ethanol by Abrams, S M, Pierce, D M, Johnston, A, Hedges, A, Franklin, R A, Turner, P

“…1. The effect of ethanol consumption (0.5 g/kg) on the pharmacokinetics of the alpha adrenoceptor antagonist indoramin, administered orally (50 mg) or…”
Get more information

Protein binding of indomethacin, methotrexate and morphine in patients with cancer by Raveendran, R, Heybroek, W M, Caulfield, M, Abrams, S M, Wrigley, P F, Slevin, M, Turner, P

“…The in vitro protein binding of indomethacin, morphine and methotrexate has been studied in two groups of ten patients each suffering from different types of…”
Get more information

The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers by Debbas, NM, Jackson, SH, Shah, K., Abrams, SM, Johnston, A., Turner, P.

“…Eight healthy volunteers received slow release nifedipine 20 mg 12 hourly, for six doses. A nifedipine pharmacokinetic profile was performed after the fifth…”
Get full text

Anticholinergic drugs, buccal ulceration and mucosal potential difference by Huston, G. J., Abrams, S. M., Turner, P.

“…Measurement of changes in buccal mucosal potential difference produced by contact with drug formulations may provide a means of predicting their mucosal…”
Get full text